Cancer detection methods and techniques
AssigneeCare Technologies, Inc.
InventorMichael Dan Burke
Life of this patent
Estimating the term…
Abstract
A method is provided for detecting and/or measuring the occurrence of an enzyme in the form of CYP1B1 in a patient for the detection of cancer in said patient. The method includes the steps of administering a reporter substrate to a patient; taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time; and analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate caused as a result of metabolism of the reporter substrate by said enzyme in said patient during said pre-determined period of time.
Claims18
A method for detecting and/or measuring an occurrence of an enzyme CYP1B1 in a patient, said method comprising the steps of:
- a) administering a reporter substrate to a patient;
- b) taking a bodily fluid and/or tissue sample from the patient after one or more pre-determined periods of time;
- and
- c) analyzing the bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of the reporter substrate known to be metabolized by CYP1B1 in the human or animal patient, wherein the reporter substrate includes any or any combination of a luteolin, 13C-luteolin, 2H-luteolin, eupatorin or 13C-eupatorin, and the reporter metabolite is 6-hydroxy-luteolin, desmethyleupatorin, formaldehyde and/or carbon dioxide.
A method for detecting and/or measuring an occurrence of an enzyme CYP1B1 in a patient sample in vitro, said method comprising the step of:
- analyzing a patient's bodily fluid and/or tissue sample in vitro for the occurrence and/or measurement of a metabolite of a reporter substrate known to be metabolized by CYP1B1 in the human or animal patient, wherein the reporter substrate includes any or any combination of a luteolin, 13C-luteolin, 2H-luteolin, eupatorin or 13C-eupatorin, and the reporter metabolite is 6-hydroxy-luteolin, and desmethyleupatorin.
Dependencies are inferred from the claim text.